Journal

Hummingbird Diagnostics Announces Publication Evaluating miR-Blood's Small RNA Expression Dataset Capabilities in Nature’s Scientific Data

Retrieved on: 
Wednesday, March 6, 2024

Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature.

Key Points: 
  • Hummingbird Diagnostics GmbH, a leader in using blood-based small RNAs for early disease detection and characterization, today announced a publication in Scientific Data, a peer-reviewed, open-access journal launched by Nature.
  • The study evaluated miR-Blood, Hummingbird Diagnostics’ small RNA expression dataset for eleven major components of human peripheral blood.
  • A highly comprehensive blood cell type expression atlas for small RNAs, miR-Blood is capable of revealing highly cell-type specific patterns of small RNA expression, enabling a deeper understanding of blood and immune biology.
  • This further supports Hummingbird’s approach of merging the analysis of tumor-derived and immune system-derived small RNA biomarkers,” remarked Dr. Rastislav Horos, Chief Technology Officer of Hummingbird Diagnostics.

Mastercard Expands HealthLock Benefit to Millions of U.S. Cardholders, Enabling Automated Detection of Potential Medical Claims Errors, Overbilling and Fraud

Retrieved on: 
Tuesday, March 5, 2024

HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.

Key Points: 
  • HealthLock helps protect a user’s medical data from data breaches and organizes deductibles, claims and provider information in one secure, digital space.
  • As new claims come in, the platform analyzes and flags each one for potential errors, fraud or overbilling.
  • Data from the Journal of the American Medical Association shows medical overbilling, fraud and abuse cost Americans hundreds of billions of dollars annually1.
  • They will have access to HealthLock’s Medical Claims Monitor, which monitors and protects your medical data privacy against fraud, at no cost.

N-803 Combined with Natural Killer Cells Showed Potential to Reduce HIV Viral Load in HIV Positive Subjects; Part of HIV Cure Study

Retrieved on: 
Tuesday, March 5, 2024

ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.

Key Points: 
  • ImmunityBio ( NASDAQ: IBRX ), a clinical-stage immunotherapy company, today announced data from a Phase 1 pilot study showed N-803 combined with natural killer cells could have the potential to reduce viral load in people living with HIV.
  • All participants in this Phase 1 study experienced significant reduction in infection levels following treatment with N-803.
  • HIV can disable NK cells—a frontline defense against viral infections—making it difficult to clear the infection.
  • The cytokine interleukin-15 (IL-15) plays a crucial role in the immune system by affecting the development, maintenance, and function of the natural killer (NK) and T cells.

Northwell Health Researcher Shows Vitamin D Could Improve Insulin-producing Cells in Children With Type 1 Diabetes

Retrieved on: 
Tuesday, March 5, 2024

To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.

Key Points: 
  • To help children and young people navigate type 1 diabetes, new research from Cohen Children’s Medical Center and The Feinstein Institutes for Medical Research at Northwell Health shows that taking vitamin D could help improve the function of insulin-producing cells.
  • View the full release here: https://www.businesswire.com/news/home/20240305266724/en/
    Dr. Benjamin Nwosu’s study shows that vitamin D could be an easier and more affordable option to help adolescents living with type 1 diabetes.
  • The research showed that by taking high-dose vitamin D, patients saw improvement in the function of insulin-producing cells which could extend the “honeymoon phase” of type 1 diabetes.
  • This research shows that by adding vitamin D, which is inexpensive and easy to obtain, one can make this phase of diabetes last longer.

Immunis.AI Announces Publication, in The Journal of Urology, of Results from Blood-Based Immune Profiling Study for Prostate Cancer Patients

Retrieved on: 
Friday, March 1, 2024

The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.

Key Points: 
  • The results validate the ability of the platform to accurately stratify risk for patients with diagnosed prostate cancer.
  • “One of the big challenges in prostate cancer management is distinguishing those patients with early prostate cancer who are appropriate for active surveillance from those who need to be aggressively treated.
  • In the study, peripheral blood samples were collected from 706 subjects with confirmed prostate cancer based on positive biopsy.
  • Using AI predictive modeling, the normalized immune profile of each patient was evaluated against known immune signatures for indolent or aggressive prostate cancer.

KAID Health launches PRIDE™ HCC coding technology and supporting services

Retrieved on: 
Thursday, February 29, 2024

This new technology and the medical coding services organization help providers code more accurately and completely while improving care.

Key Points: 
  • This new technology and the medical coding services organization help providers code more accurately and completely while improving care.
  • KAID Health has already proven its technology can reduce labor costs and audit risks, including allowing healthcare organizations to appropriately navigate the challenges of HCC v28 and other risk-adjustment models.
  • In addition to launching PRIDE, KAID Health has created a technology-powered Coding Services Group.
  • KAID Health’s Coding Services Group delivers providers best-in-class coder training, physician education, and outsourcing options, making HCC improvement effortless.

Yelp Publishes 2023 Trust & Safety Report

Retrieved on: 
Wednesday, February 28, 2024

Yelp Inc. (NYSE:YELP), the company that connects people with great local businesses, today released its annual Trust & Safety Report , providing insights into the extensive measures the company took in 2023 to mitigate attempts to mislead consumers, including efforts that were orchestrated off of Yelp.

Key Points: 
  • Yelp Inc. (NYSE:YELP), the company that connects people with great local businesses, today released its annual Trust & Safety Report , providing insights into the extensive measures the company took in 2023 to mitigate attempts to mislead consumers, including efforts that were orchestrated off of Yelp.
  • “As we release our 2023 Trust & Safety Report, it’s clear that our rigorous approaches that blend advanced technology with dedicated human moderators uphold Yelp as a reliable resource for our users.
  • In fact, the Journal of Marketing Research recently deemed Yelp as a ‘Guardian of Trust’ and we are consistently working on new ways to further maintain the trust and safety of our users.”
    Key findings from the 2023 Yelp Trust & Safety Report:
    Approximately 22 million reviews were contributed to Yelp in 2023, up nearly 6% from 2022.1
    Of these reviews, about 78% were recommended by Yelp’s automated recommendation software , which helps surface the most helpful and reliable content to consumers.
  • 1 Data is sourced globally as of Dec. 31, 2023, and reflects reviews contributed from Jan. 1, 2023 through Dec. 31, 2023.

Castle Biosciences Reports Fourth Quarter and Full-Year 2023 Results

Retrieved on: 
Wednesday, February 28, 2024

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced its financial results for the fourth quarter and year ended Dec. 31, 2023.
  • DecisionDx-SCC test reports delivered in the quarter were 3,530, compared to 1,845 in the fourth quarter of 2022, an increase of 91%.
  • DecisionDx-UM test reports delivered in the quarter were 405, compared to 432 in the fourth quarter of 2022, a decrease of 6%.
  • Castle Biosciences will hold a conference call on Wednesday, Feb. 28, 2024, at 4:30 p.m. Eastern time to discuss its fourth quarter and full-year 2023 results and provide a corporate update.

Advancing Skin Cancer Detection: American Academy of Dermatology Journal Publishes DermaSensor's Breakthrough Melanoma Detection Results From A Major, Multicenter Trial

Retrieved on: 
Wednesday, February 28, 2024

In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.

Key Points: 
  • In addition, the Negative Predictive Value (NPV) of 98.1% (95% CI, 91.8%-99.6%) indicates a high level of reliability for a negative device result of “Monitor”.
  • For a positive device result of “Investigate Further”, a 1-10 score is also provided to indicate the degree of similarity to malignant lesions.
  • The study found that the likelihood of melanoma for these positive results ranged from 10.3% for low scores (i.e., 1-3) to 47.4% for high scores (i.e., 8-10).
  • This automated, objective device can help in the fight against skin cancer, and the DermaSensor team is dedicated to making a meaningful contribution to its detection and prevention."

BeiGene Receives Positive CHMP Opinion for Tislelizumab as Treatment for Non-Small Cell Lung Cancer

Retrieved on: 
Monday, February 26, 2024

As monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy.

Key Points: 
  • As monotherapy for the treatment of adult patients with locally advanced or metastatic NSCLC after prior platinum-based therapy.
  • Patients with EGFR mutant or ALK positive NSCLC should also have received targeted therapies before receiving tislelizumab.
  • Tislelizumab is also under review by the FDA as a first-line treatment for patients with unresectable, recurrent, locally advanced, or metastatic ESCC.
  • BeiGene has launched more than 17 potentially registration-enabling trials with tislelizumab with over 13,000 patients enrolled to-date, of which 15 have already reported positive readouts.